Payment overview · 2025
General Payments
$259.15
15 reported records · 5 companies
Healthcare provider profile · identity verified
Justin A Bennett
Allopathic & Osteopathic Physicians|Family Medicine · LOUISVILLE, TN · NPI 1396011722
Verified facts
What the public records show
CMS Open Payments records show Justin A Bennett received $259.15 in general payments during 2025 across 15 reported records.
AstraZeneca Pharmaceuticals LP accounted for 54.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 190 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $141.91 | 54.8% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $34.08 | 13.2% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.02 | 13.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $27.57 | 10.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.57 | 8.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $259.15 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $82.46 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $80.24 | 4 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $34.02 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $27.57 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $27.57 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $21.57 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.22 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.22 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.22 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.86 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 190 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 84 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
84 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
190 | 42 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 669 | 185 |
| Levothyroxine Sodium | Levothyroxine Sodium | 530 | 113 |
| Amlodipine Besylate | Amlodipine Besylate | 510 | 132 |
| Gabapentin | Gabapentin | 489 | 92 |
| Lisinopril | Lisinopril | 449 | 115 |
| Omeprazole | Omeprazole | 438 | 113 |
| Pantoprazole Sodium | Pantoprazole Sodium | 408 | 100 |
| Losartan Potassium | Losartan Potassium | 398 | 101 |
| Potassium Chloride | Potassium Chloride | 307 | 76 |
| Furosemide | Furosemide | 264 | 69 |
| Trazodone Hcl | Trazodone Hcl | 264 | 67 |
| Simvastatin | Simvastatin | 254 | 61 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 248 | 66 |
| Metoprolol Succinate | Metoprolol Succinate | 220 | 58 |
| Metoprolol Tartrate | Metoprolol Tartrate | 213 | 55 |
| Prednisone | Prednisone | 211 | 127 |
| Tamsulosin Hcl | Tamsulosin Hcl | 209 | 50 |
| Allopurinol | Allopurinol | 204 | 47 |
| Metformin Hcl | Metformin Hcl | 200 | 51 |
| Eliquis | Apixaban | 190 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 179 | 51 |
| Metformin Hcl Er | Metformin Hcl | 179 | 50 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 178 | 50 |
| Fluticasone Propionate | Fluticasone Propionate | 162 | 42 |
| Zolpidem Tartrate | Zolpidem Tartrate | 159 | 25 |
| Buspirone Hcl | Buspirone Hcl | 156 | 35 |
| Sertraline Hcl | Sertraline Hcl | 155 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 147 | 33 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 146 | 30 |
| Meloxicam | Meloxicam | 142 | 34 |
| Tizanidine Hcl | Tizanidine Hcl | 142 | 35 |
| Carvedilol | Carvedilol | 141 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 138 | 35 |
| Jardiance | Empagliflozin | 118 | 32 |
| Spironolactone | Spironolactone | 115 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 112 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 111 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 106 | 33 |
| Montelukast Sodium | Montelukast Sodium | 105 | 27 |
| Lorazepam | Lorazepam | 100 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 92 | 25 |
| Mirtazapine | Mirtazapine | 90 | 19 |
| Alendronate Sodium | Alendronate Sodium | 89 | 25 |
| Famotidine | Famotidine | 84 | 22 |
| Ozempic | Semaglutide | 84 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 83 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 81 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 79 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 76 | 66 |
| Citalopram Hbr | Citalopram Hydrobromide | 75 | 22 |
| Alprazolam | Alprazolam | 73 | 20 |
| Glimepiride | Glimepiride | 73 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 70 | 19 |
| Lovastatin | Lovastatin | 68 | 18 |
| Fluconazole | Fluconazole | 66 | 30 |
| Clonazepam | Clonazepam | 65 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 63 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 60 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 60 | 13 |
| Pregabalin | Pregabalin | 59 | 11 |
| Celecoxib | Celecoxib | 58 | 13 |
| Glipizide | Glipizide | 56 | 14 |
| Benazepril Hcl | Benazepril Hcl | 55 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 54 | 34 |
| Doxazosin Mesylate | Doxazosin Mesylate | 53 | 16 |
| Promethazine Hcl | Promethazine Hcl | 53 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 51 | 15 |
| Estradiol | Estradiol | 50 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 49 | suppressed |
| Bupropion Xl | Bupropion Hcl | 48 | 16 |
| Glipizide Er | Glipizide | 48 | 13 |
| Propranolol Hcl | Propranolol Hcl | 45 | suppressed |
| Atenolol | Atenolol | 44 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 43 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 43 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 42 | 11 |
| Sucralfate | Sucralfate | 42 | 13 |
| Synthroid | Levothyroxine Sodium | 42 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 41 | 38 |
| Valsartan | Valsartan | 39 | suppressed |
| Lamotrigine | Lamotrigine | 37 | suppressed |
| Ondansetron Odt | Ondansetron | 37 | 14 |
| Fenofibrate | Fenofibrate | 36 | 11 |
| Bumetanide | Bumetanide | 35 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | suppressed |
| Nystatin | Nystatin | 35 | 19 |
| Ezetimibe | Ezetimibe | 34 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 33 | 30 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Verapamil Er | Verapamil Hcl | 33 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 32 | suppressed |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Topiramate | Topiramate | 29 | suppressed |
| Methocarbamol | Methocarbamol | 28 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Acyclovir | Acyclovir | 26 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 26 | 12 |
| Irbesartan | Irbesartan | 26 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Gemfibrozil | Gemfibrozil | 25 | suppressed |
| Lansoprazole | Lansoprazole | 24 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 16 |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Cefdinir | Cefdinir | 17 | 14 |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 17 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | 14 |
| Diazepam | Diazepam | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Movantik | Naloxegol Oxalate | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Eplerenone | Eplerenone | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Timolol Maleate | Timolol Maleate | 11 | suppressed |
| Yuvafem | Estradiol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $259.15 · 15 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, BREZTRI, COMIRNATY, ELIQUIS, GVOKE HYPOPEN, NURTEC ODT, Ozempic, PREVNAR 20, Rybelsus, TRELEGY ELLIPTA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error